Breaking News Instant updates and real-time market news.

MTNB

Matinas BioPharma

$1.21

-0.01 (-0.82%)

07:36
01/08/18
01/08
07:36
01/08/18
07:36

Matinas achieves statistical endpoint for success in MAT2203 Phase 2a study

Matinas BioPharma announced that investigators from the National Institutes of Health have relayed to the company positive data from a third patient enrolled in the collaborative Phase 2a clinical study of Matinas' lead anti-infective product candidate MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis infection. This third patient, with long-standing azole resistant mucocutaneous candidiasis, met the primary endpoint of the Phase 2a study in achieving greater than or equal to 50% clinical response with treatment of MAT2203. MAT2203 was well tolerated with any adverse events observed being mild in severity and unrelated to study drug. With this third positive response, the study has met its statistical hurdle for success. MAT2203 is the company's orally-administered, encochleated formulation of the broad spectrum fungicidal medication amphotericin B. Matinas BioPharma's proprietary lipid-crystal nano-particle formulation of amphotericin B has a novel mechanism of absorption and distribution to infected tissues and has the potential to transform the way this potent fungicidal agent is administered and used in clinical practice.

MTNB Matinas BioPharma
$1.21

-0.01 (-0.82%)

07/10/17
ROTH
07/10/17
INITIATION
Target $9
ROTH
Buy
Matinas BioPharma initiated with a Buy at Roth Capital
Roth Capital analyst Michael Higgins started Matinas BioPharma with a Buy rating and a $9 price target.
07/10/17
07/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SeaSpine (SPNE) initiated with a Buy at H.C. Wainwright. 2. Puma Biotechnology (PBYI) resumed with an Outperform at Leerink. 3. SCYNEXIS (SCYX) initiated with a Buy at Roth Capital. 4. Tabula Rasa HealthCare (TRHC) initiated with a Buy at Chardan. 5. Matinas BioPharma (MTNB) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.